FDA Clears Letybo for Glabellar Line Treatment

The FDA approved Letybo for use in the United States in 2024 to offer a new botulinum toxin option.

Updated on Oct. 26, 2026 in Beauty

Bold vector editorial illustration of two frosted glass medical ampoules on a white surface, representing cosmetic neurotoxin treatment. — The FDA approved Letybo in 2024, introducing a new botulinum toxin option for the treatment of glabellar lines in the United States. AI Illustration. Upload story photo >

Live Poll

Is now a good time to consider cheaper alternatives to established cosmetic neuromodulator brands?

In 2024, the FDA approved the use of Letybo in the United States for the treatment of glabellar lines. The neuromodulator contains botulinum toxin A and serves as an alternative to existing market options.

Why it matters

Letybo provides patients and clinics with a new choice in cosmetic neurotoxin treatments. It features a unique formulation containing fewer complexing proteins than many competitors.

Letybo costs between $9 and $12 per unit compared to the $12 to $18 range for Botox, with the average treatment for glabellar lines requiring 25 units. Hugel also allows practices to order individual vials, bypassing the 250-vial minimum purchase requirement found elsewhere.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical products in the United States.

Hugel

Hugel is the South Korea-based biopharmaceutical company that produces Letybo.

The details

Letybo works by blocking acetylcholine to prevent muscle contractions. Patients can expect results to take effect in approximately three days, with outcomes lasting for 12 to 16 weeks.

The FDA cleared Letybo for U.S. use in 2024.
Most patients see the effects of Letybo in three days.
Botox typically takes 5 to 7 days to show results.
Results from a Letybo treatment last for 12 to 16 weeks.

Culture Shift

The introduction of Letybo signals a shift toward greater competition in the aesthetic medical market, challenging the long-standing prevalence of major brands. This move highlights an industry-wide transition toward offering more cost-effective and flexible procurement options for clinics.

Patients may find that more local clinics offer this treatment due to the manufacturer's flexible purchasing terms for individual vials. Those seeking cosmetic treatments can discuss the pricing differences between Letybo and other established options with their local provider.

The takeaway

Patients considering neuromodulator treatments should note that onset times and costs vary significantly between available options. Consulting with a qualified provider helps determine whether a new product like Letybo or an established alternative fits your specific aesthetic goals.